Scarica l'app Stockscreener
4.84
2.62%
-0.13
Pre-mercato:
4.85
0.010
+0.21%
Candel Therapeutics Inc Borsa (CADL) Ultime notizie
Geode Capital Management LLC Grows Stock Position in Candel Therapeutics, Inc. (NASDAQ:CADL) - Defense World
S3e01 Life Changing Innovation with Paul Peter Tak, CEO of Candel Therapeutics - iHeart
A new trading data show Candel Therapeutics Inc (CADL) is showing positive returns. - Sete News
Candel Therapeutics to Present Prostate Cancer Trial Data By Investing.com - Investing.com South Africa
Candel Therapeutics to Present Prostate Cancer Trial Data - Investing.com
Candel Therapeutics Announces Oral Presentation of CAN-2409 Data at 2025 ASCO Annual Meeting - Nasdaq
Candel Therapeutics Announces Oral Presentation of Positive - GlobeNewswire
Major Phase 3 Trial Results: Breakthrough Prostate Cancer Treatment Data to be Revealed at ASCO 2025 - Stock Titan
Candel Therapeutics to present Phase 3 prostate cancer data at 2025 ASCO Annual Meeting - Proactive Investors
How To Trade (CADL) - news.stocktradersdaily.com
Critical Review: Candel Therapeutics (NASDAQ:CADL) & ProKidney (NASDAQ:PROK) - Defense World
H.C. Wainwright maintains Buy on Candel Therapeutics stock By Investing.com - Investing.com Canada
H.C. Wainwright maintains Buy on Candel Therapeutics stock - Investing.com Australia
Private Sector Steps Up in Cancer Research as Federal Support Wavers - Baystreet.ca
Candel Therapeutics reveals new data showing better outcomes for glioma patients using CAN-2409 - Proactive financial news
Candel Therapeutics Announces Publication of Phase 1b - GlobeNewswire
Candel Therapeutics announces publication of Phase 1b trial data on CAN-2409 - TipRanks
Candel Therapeutics Announces Publication of Phase 1b Clinical Trial Data on the Combination of CAN-2409 and Nivolumab plus Standard of Care in Newly Diagnosed High-Grade Glioma Patients - GlobeNewswire
Candel Therapeutics reports breakthrough data for late-stage lung cancer – ICYMI - Proactive financial news
Candel Therapeutics reports breakthrough data for late-stage lung cancer – ICYMI | NASDAQ:CADL - Proactive Investors
Candel Therapeutics shares positive survival data for investigational immunotherapy in NSCLC - Proactive financial news
Candel Therapeutics Reports Prolonged Survival In Mid-Stage Study For Pretreated Lung Cancer Patients - AOL.com
Candel Therapeutics Stock Price, Quotes and Forecasts | NASDAQ:CADL - Benzinga
Candel Therapeutics Shares Are Down Today: What's Going On? - Benzinga
Candel Therapeutics Clinical Trial for CAN-2409 Demonstrates Promising Survival Extensions for NSCLC Patients Who Failed Previous Therapies - citybiz
Candel Therapeutics Reports Positive Phase 2a Trial Results - TipRanks
Trading (CADL) With Integrated Risk Controls - news.stocktradersdaily.com
Candel Therapeutics Reports Both Prolonged Median Overall - GlobeNewswire
Candel Therapeutics Reports Final Phase 2a Survival Data for Lung Cancer Treatment - MarketScreener
Candel Therapeutics Reports Both Prolonged Median Overall Survival And Long Tail Of Survival In Phase 2A Clinical Trial Of CAN-2409 In Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Non-Responsive To Immune Checkpoint Inhibitor (ICI) Treat - MarketScreener
Candel Therapeutics reports positive survival data for CAN-2409 in advanced lung cancer trial - Proactive Investors
Candel Therapeutics Reports Both Prolonged Median Overall Survival and Long Tail of Survival in Phase 2a Clinical Trial of CAN-2409 in Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Non-Responsive to Immune Checkpoint Inhibitor (ICI) Treatm - The Manila Times
Breakthrough: Cancer Drug CAN-2409 Achieves 24.5-Month Survival in Advanced Lung Cancer Patients - Stock Titan
Small cap wrap: Nano One Materials, EnWave, Summit Therapeutics... - Proactive financial news
Bears are Losing Control Over Candel Therapeutics (CADL), Here's Why It's a 'Buy' Now - Zacks Investment Research
CADLCandel Therapeutics, Inc. Latest Stock News & Market Updates - Stock Titan
Candel therapeutics CEO sells $229,624 in stock By Investing.com - Investing.com Canada
Insider Sell Alert: Paul Tak Sells 26,172 Shares of Candel Thera - GuruFocus
Candel therapeutics chief scientific officer sells $281,672 in stock By Investing.com - Investing.com South Africa
Candel Therapeutics’ chief medical officer sells $396,995 in stock By Investing.com - Investing.com Canada
Candel therapeutics CEO sells $229,624 in stock - Investing.com India
Candel Therapeutics Executives Sell Shares Under Trading Plans - TradingView
Candel Therapeutics’ chief medical officer sells $396,995 in stock - Investing.com
Small cap wrap: Santacruz Silver, GoviEx Uranium, Candel Therapeutics... - Proactive Investors
Candel Therapeutics Partners With IDEA Pharma To Advance CAN-2409 Cancer Immunotherapy - Nasdaq
Candel Therapeutics partners with IDEA Pharma on commercialization of CAN-2409 - Proactive Investors
Candel Therapeutics Partners With IDEA Pharma for CAN-2409 Commercialization -March 20, 2025 at 08:29 am EDT - MarketScreener
Candel Therapeutics and IDEA Pharma Announce Strategic - GlobeNewswire
Breakthrough Prostate Cancer Drug Shows 30% Better Results as Candel Secures Key Partnership - Stock Titan
0.78%
2.03%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):